Clinical Trials Logo

Arthrogryposis clinical trials

View clinical trials related to Arthrogryposis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06391450 Not yet recruiting - Clinical trials for Autosomal Dominant Polycystic Kidney

Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)

EMPA-PKD
Start date: May 2024
Phase: Phase 4
Study type: Interventional

The EMPA-PKD trial is assessing the safety of empagliflozin in patients with rapid progressive ADPKD with and without concomitant tolvaptan use by monitoring kidney growth and the rate of loss of kidney function.

NCT ID: NCT06372821 Not yet recruiting - Alzheimer Disease Clinical Trials

A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

NIO-SILK
Start date: May 2024
Phase: Phase 1
Study type: Interventional

This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells. In Alzheimer's disease (AD) it builds up in the brain, causing damage. Abnormal tau proteins cling to each other forming 'tangles' inside nerve cells, which interfere with how the nerve cells work, and eventually die. This is what causes the symptoms of dementia. It is thought that NIO752 reduces production of tau.

NCT ID: NCT06192134 Not yet recruiting - Arthrogryposis Clinical Trials

Continuous Passive Motion Device for Children With Arthrogryposis

Start date: June 2024
Phase: N/A
Study type: Interventional

We are investigating a continuous passive motion device to exercise the knee of young children with arthrogryposis after they have had knee surgery.

NCT ID: NCT06140329 Not yet recruiting - Clinical trials for Autosomal Dominant Optic Atrophy

Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation

Start date: February 2024
Phase:
Study type: Observational

The purpose of this study is to characterize the disease progression of confirmed OPA1 mutation-associated autosomal dominant optic atrophy (ADOA) by evaluating the changes in ocular structural and functional outcomes.

NCT ID: NCT06130592 Not yet recruiting - Clinical trials for Arthrogryposis Multiplex Congenita (AMC)

Technical Feasibility Study of Ultrasound Muscle Imaging in Antenatal Ultrasound

FetUS
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

The objective of the study is to evaluate the performance of muscle ultrasound sections on antenatal ultrasound between 21-24 amenorrhea weeks for the screening of muscle atrophy, in a sample of low-risk and high-risk pregnancies of congenital multiple arthrogryposis